Corticosteroid Pulses for Hospitalized Patients with COVID-19: Effects on Mortality

Table 2

Primary and secondary outcomes of the global and matched population.

Outcome	Overall population			Matched population
	Methylprednisolone ()	Usual care ()	value	Methylprednisolone ()	Usual care ()	value
Primary outcome
60-day mortality	37/122 (30.3%)	57 (42.8%)	0.026	34/115 (29.6%)	39/88 (44.3%)	0.022
Secondary outcomes
30-day mortality	37/122 (30.3%)	56/133 (42.1%)	0.034	34 (29%)	38 (43.2%)	0.031
Hyperglycemia	10 (8.0%)	5 (3.7%)	n.s	10 (8.5%)	5 (5.6%)	n.s
ICU admission	23 (18.5%)	26 (19.5%)	n.s	19 (16.2%)	21 (23.8%)	n.s
In-hospital mortality	36 (29%)	56 (42.1%)	0,02	33 (28.2%)	38 (43.2%)	0.019
LOS (days)	8 (10)	12 (13)		8 (11)	12 (12)	n.s
Mechanical ventilation	19 (15.3%)	25 (18.7%)	n.s	16 (13.6%)	21 (23.8%)	n.s
Nosocomial infection	29 (23.4%)	32 (24%)	n.s	26 (22.2%)	25 (28.4%)	n.s

Data are shown as the median (IQR) or (%).ICU: intensive care unit; LOS: length of stay; n.s: not significant.